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Abstract
Background: Severe mental disorders like psychotic disorders including schizophrenia and schizoaffective disorders
have a 12-month-prevalence of 2.6, bipolar disorders of 1.5 % in Germany. The relapse risk is high; so many patients
need intensive monitoring and lifelong treatment. A high medication adherence is essential for a successful treatment.
But in practice, medication adherence is low and decreases over time. Telemedical care concepts might improve
treatment and bridge gaps between in- and outpatient treatment.
A telemedical care concept based on regular telephone calls and short text messages was developed. The primary
objective is to assess whether regular telephone calls and text messages can improve the medication adherence of
patients. Secondary objectives are the reduction of rehospitalization rates, the improvement of quality of life and of the
severity of symptoms.
Methods/design: The Tecla study (Post stationary telemedical care of patients with severe psychiatric disorders) is a
two-armed prospective randomized controlled trial. The participants in the intervention group receive in addition to
usual care regular telephone calls every 2 weeks and weekly text messages on patient-individual topics during a
6 months period. Patients in the control group receive only regular care. Inclusion criteria are a physician-diagnosed
bipolar disorder, schizoaffective disorder or schizophrenia and a signed informed consent. Exclusion criteria are planned
inpatient treatments within the next 6 months and being non-reachable by phone. After 3 and 6 months both groups
receive follow up assessments.
Discussion: The primary objective of this study is the medication adherence that is measured with the Medication
Adherence Report Scale, German version (MARS-D). The MARS-D is a self-report with five items. Adherent behaviour is
mostly overestimated using self-reports. The strength of the MARS-D is to detect non-adherent behaviour. The original
Medication Adherence Report Scale in English language (MARS-5) was developed to encourage the patient to answer
truthfully to the questions that are asked in a non-threatening and non-judgmental way to minimize social desirability
bias in admitting non-adherent behaviour.
Trial registration: This study is registered at 2015\05\21at the German Clinical Trials Register DRKS00008548.
Keywords: Mental health disorders, Schizophrenia, Psychotic disorders, Bipolar disorders, Telemedical care,
Telemedicine, Telephone, Text messages
* Correspondence: ulrike.stentzel@uni-greifswald.de
1Institute for Community Medicine, University Medicine Greifswald,
Ellernholzstraße 1-2, 17487 Greifswald, Germany
Full list of author information is available at the end of the article
© 2015 Stentzel et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




Nineteen new schizophrenia-cases per 100,000 people per
year are diagnosed in Germany [1]. Prevalence rates of
mental disorders are high all over the world, also in Europe
and Germany. The lifetime prevalence of schizophrenia
worldwide is estimated as 1 % of the population. The 12-
month-prevalence of schizophrenia and other psychotic
disorders in the German population is about 2.6 %; the 12-
month-prevalence of bipolar disorders about 1.5 % [2]. In
Germany 2 to 4 % of the total health care costs are caused
by schizophrenic disorders [1]. Mental disorders are associ-
ated with a high disease burden. People with current men-
tal disorders have three times as much days of limitation
than people without any mental disorder [2]. Worldwide,
schizophrenia is one of the ten diseases with the highest
number of years of life lived with disability (YLD) [1]. This
also leads to high social costs [3] because mental disorders
are the most common cause for early retirement, work
losses and reduced work productivity [4]. The restricted
participation in social and professional life often causes a
severe reduction of quality of life [1].
Utilization and adherence
Treatment rates of mental disorders in general are low.
The Study of Health in Pomerania (SHIP) [5] revealed a
treatment rate for mental disorders of 20 % [6]. In the
Mental Health Supplement of the German National Health
Interview and Examination Survey (GHS-MHS) treatment
rates for psychotic disorders (including schizophrenia) of
30.3 % of the cases and of 82.4 % for highly co-morbid
cases were found. Patients with bipolar disorders received
treatment in 42.2 % of the cases (62.4 % treatment in
highly co-morbid cases) [7].
The diagnosis of schizophrenia implies in most cases a
lifelong medical treatment. In the acute stages of schizo-
phrenia, therapy is applied in the hospital. In this stage,
drug therapy is essential to achieve a rapid and effective
reduction of acute psychotic symptoms. After discharge
from the hospital, adherence to medication is essential to
avoid relapses. However, non-adherence is one of the
major problems in patients with schizophrenia [8]. The
proportion of adherent patients is 35–50 % in patients
with schizophrenia and bipolar disorders [9–11]. In the
outpatient setting, the adherence of patients taking atyp-
ical antipsychotics drops to 55 % after 12 months [12].
Non-adherence is associated with a higher risk of psychi-
atric hospitalizations [13]. Without drug therapy the
relapse rate is about 70 % in the first year and about 80 %
in the second year after starting drug treatment [14–16].
With drug therapy the recurrence rate is significantly
lower: about 30 % in the first year and about 50 % in the
second year [1].
In total 93 % of the patients with schizophrenia in
Germany are treated in outpatient psychotherapeutic facil-
ities (e.g. practices, psychiatric walk-in clinics or day-care).
Especially in rural regions, waiting lists are long. A survey
among practicing psychotherapists in Germany showed
that adult patients have to wait on average 1.9 months for
an initial interview and 4.6 months for psychotherapy [17].
Telemedical care
Telemedical concepts have a potential to support the treat-
ment of psychiatric patients and to provide new options in
patient care. Several studies have evaluated the possibilities
and limitations of telemedical care in the treatment of
patients with schizophrenia. Salzer et al. [18] conducted a
study with n = 32 schizophrenic patients consisting of brief
weekly telephone-based interviews. The results showed
that telephone interventions are acceptable and feasible.
Because of the small study sample, these results were seen
as preliminary data.
Leach and Christensen performed a systematic review
about telephone-based interventions for patients with
mental disorders (six in the area of depression, three of
anxiety, three of eating disorders, one of substance abuse
and one of schizophrenia). Although the included
studies all had small simple sizes, they showed positive
results [19].
Alvarez-Jimenez et al. conducted a systematic review
examining the usability, acceptability, feasibility, safety or
efficacy of user-led, internet- or mobile-based interventions
with patients of the schizophrenia-disorders spectrum.
Twelve studies were included. Patients mainly used the
internet and mobile phone based interventions. The
authors conclude that online, social media and mobile
technologies were acceptable and feasible for patients [20].
Kasckow et al. summarized a systematic review includ-
ing 18 studies with telephone-based, internet-based or
video-based telehealth systems for patients with schizo-
phrenia, that telephone, internet and video-interventions
appears to be feasible [21].
Improving medication adherence using telemedical
methods was discussed in several studies. In 2008 a ran-
domized controlled trial was published that examined tele-
phone intervention problem solving (TIPS) for patients
with schizophrenia [22]. These telephone interventions
were initiated weekly by telenurses and improved signifi-
cantly the patient’s adherence to their psychiatric medica-
tion. Adherence was measured by pill counting and record
review. The participants in the intervention showed an ad-
herence of on average 80 %, while in control participants
this rate was 60 %.
A study in Spain examined a telephone based strategy to
improve adherence to antipsychotic treatment in schizo-
phrenia. Nine hundred twenty-eight patients received a
monthly telephone call by a nurse to assess therapeutic
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adherence and subjective attitude towards medication
over a period of 4 months. Being adherent was defined
as the intake of at least 60 % of the prescribed medica-
tion dose. Patients in the intervention group (n = 410)
were significantly more adherent (OR = 3.3 95 % CI
1.6–6.6, P = 0.0001) than patients in the control group
(n = 402) [23].
The study Mobile Assessment and Treatment for
Schizophrenia (MATS) with 55 participating patients
examined the use of mobile phone text messaging.
6 days a week individualized text messages were sent to
the participants addressing the topics medication
adherence, social activities and auditory hallucinations
during the 12-week-intervention-period. Participants
who were living independently achieved a significant
improvement in medication adherence and benefited
more than participants living in assisted living facilities.
This is probably due to the fact, that the participants in
assisted living facilities already have support and assist-
ance in taking medications. This study was a pilot study
without a control group [24].
Summarized, first studies with telemedicine concepts
for patients with schizophrenia show positive results.
However, evidence based on methodically sound studies
with a sufficient number of participants is still limited.
The intention of Tecla study (Post stationary telemedi-
cal care of patients with severe psychiatric disorders) is
to improve medical care for patients with severe mental
disorders in Western-Pomerania/Germany using a tele-
medical intervention concept on the basis of regular,
individualized telephone calls and text-messages.
Methods/design
The Tecla study
The outlined study Tecla is designed according to the
SPIRIT Guidelines [25]. Tecla is a cooperation between the
Institute for Community Medicine and the Department of
Psychiatry and Psychotherapy, both University Medicine
Greifswald, and the Bethanien Hospital for Psychiatry,
Psychosomatics and Psychotherapy Greifswald gGmbH.
An Integrated Telemedicine Centre is affiliated to the
Institute for Community Medicine [26–28].
The study region Western-Pomerania is located in the
very northeast of Germany in the federal state of
Mecklenburg-Western Pomerania. It is a sparsely popu-
lated rural region with 460,000 inhabitants. Both in- and
outpatient psychiatric and psychotherapeutic facilities
and walk-in clinics are mostly located in the larger
towns of the region.
Research objectives
Primary objective of the Tecla Study is a better medica-
tion adherence after 6 months of additional telemedical
treatment in the intervention group compared to a
control group receiving usual care.
Secondary outcomes are a lower proportion of rehos-
pitalized participants after 6 months, a longer time
without unplanned rehospitalization, an improvement
in quality of life and an improvement in the severity of
the psychopathology.
Additionally, the acceptance of the telephone and text
message interventions by the participants will be evalu-
ated in the intervention group.
Study design
The Tecla study is a controlled randomized prospective
intervention study. Participants are recruited shortly before
their discharge from the psychiatric hospital after inpatient
or combined inpatient/outpatient treatment. All partici-
pants receive a comprehensive baseline interview with a
study-psychologist. After the baseline interview the partici-
pants are assigned at random to the intervention or control
group. Participants in the intervention group receive phone
calls every 2 weeks conducted by specially trained nurses
as well as weekly individualized text messages additional to
usual care. The duration of the intervention period is
6 months. The participants in the control group receive
usual care. After baseline, a first follow-up assessment is
conducted after 3 months. The final follow-up is con-
ducted after 6 months. Both follow ups are conducted by
telephone. The structure of the study is shown in a flow
chart in Fig. 1.
Power/sample size
The sample size estimate was based on the medication
adherence, measured as a score with the questionnaire
MARS-D. Given an adherent behaviour in the interven-
tion group of 80 % (corresponding to a mean score of 19)
and a lower adherent behaviour in the control group of
60 % (corresponding to a mean score of 15) after 6 months,
a total sample size of 128 is needed (standard deviation
8.0 for both, alpha = 0.05, power = 0.80). Assuming a lost
to follow up about 50 %, we will include 190 patients to
the study.
Recruitment and participants
Patients are recruited from three psychiatric hospitals in
the region shortly before their discharge. The inclusion cri-
teria are met if the patient is at least 18 years old, has a
medical diagnosis in the field of bipolar disorders (ICD-10
F31), schizoaffective disorders (ICD-10 F25) or any form of
schizophrenia (ICD-10 F20). Patients with already sched-
uled inpatient treatments within the next 6 months are
excluded. In addition, patients can’t participate, if they are
not reachable by phone. The study psychologist visits the
participating hospital departments to inform the patients
on site and invite them to participate in the study. All
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patients have to give written informed consent. Therein
the patients declare consent to
 be contacted by the study nurse over a period of
6 months by call and by text messages
 to the scientific evaluation of the collected data in a
pseudonymised form
 to be possibly contacted again after the participation
in the project to ascertain how further treatment is
progressing
 the use of further data (like data from hospital
information systems about other in- or outpatient
treatments or data of the statutory health insurance)
in the evaluation.
Patients can withdraw their consent or parts of it any-
time and without giving reasons. The withdrawal does
not create disadvantages.
The recruitment phase of the project started February
2015.
Baseline and follow-up interviews
Shortly before their discharge from the hospital, all partic-
ipants receive a baseline interview conducted on site by
the study psychologist. The baseline interview consists of
the assessment of personal data (name, address, telephone
number, date of birth), diagnoses, medication, by the
patients’ desired topics for the telephone calls and several
standardized questionnaires covering the outcomes of the
study. The diagnoses are taken from the medical record.
In addition the Structured Clinical Interview for DSM-IV
(SCID I) is performed, but only the specific sections about
affective disorders and the sections about the psychotic
disorders [29]. Topics for telephone calls selected from a
list by the patient are medication, housing/living, work,
finances, spare time, friends, family, partnership, everyday
life, diseases and others.
The medication adherence is measured using the
Medication Adherence Report Scale, German version
(MARS-D) [30]. The MARS-D consists of five items,
detecting non-adherent behaviour by self-report. It is
Fig. 1 Flow chart of the study
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known that patients tend to overestimate their adherence
[31–33] or to conceal non-adherent behaviour [30]. The
MARS-5 (original Medication Adherence Report Scale in
English language) was developed to take the frequency of
non-adherent behaviour into account and to encourage
the patient to answer truthfully to the questions that are
asked in a non-threatening and non-judgmental way to
minimize social desirability bias [34, 35].
The mental health status is measured by the Brief
Psychiatric Rating Scale (BPRS). This instrument consists
of 18 items to measure the severity of psychiatric symp-
toms [36, 37]. The Young Mania Rating Scale (YMRS) in
German Language will be used for the assessment and
quantification of manic symptoms [38].
Quality of life will be measured on the basis of the
short version of the subjective instrument World Health
Organization Quality of Life (WHOQOL-BREF), which
is designed for generic use [39, 40].
The psychological, social and occupational function levels
will be assessed by the Global Assessment of Functioning
(GAF) on a scale from 1 to 100, intended as a hypothetical
continuum of mental health (score 91–100) to illness
(score 1–10) [41].
In the baseline interview the following issues will also
be assessed in a standardized computer assisted personal
interview:
– Socio-demographic information
– Side effects of medication according to a list of
common side effects of psychotropic drugs
– Social support (F-SozU, short form with 14 items) [42]
– Short scale social desirability-gamma (KSE-G) [43]
– Resilience scale (RS-11, short form with 11 items) [44]
– Use of alcohol, drugs and smoking status [45, 46]
– Childhood Trauma Questionnaire (CTQ) [47]
The 3- and 6-months-follow-ups will be conducted by
telephone by the nurses of the telemedicine centre as a
computer assisted personal interview. In both follow-ups,
the MARS-D, WHOQOL-BREF, the side effects of
medication, social support, social desirability, the resili-
ence scale and furthermore, changes in medication and
the utilization of in- and outpatient treatment will be
assessed. The utilization of other treatments will be
assessed by asking whether the participants have visited
a general practitioner or other specialized physicians
including psychotherapist/psychiatrists within the last
three respectively 6 months and if so, how often. Also
the number and duration of hospital stays are ques-
tioned. The GAF will be assessed only in the 6-months-
follow-up.
In the 6-months-follow-up the participants in the
intervention group will also be asked how they evaluate
the intervention (Table 1).
Intervention
The intervention consists of telephone calls every 2 weeks
and standardized weekly text messages, conducted by spe-
cially trained nurses in a telemedicine centre. Participants
can send answers to the text messages or use this medium
to contact the nurses. The intervals can be reduced if
necessary. Additionally, the participants can contact the
nurses within office hours. If appropriate, individualized
text messages are being sent.
Each telephone call starts with a question about the
health condition of the participants: How do you do feel
today? What went well today or yesterday? Are there any
problems? Afterwards the topics that were selected in the
baseline interview are being discussed. These topics can
be changed, if participants want to talk about other topics.
After discussing the chosen topic, the participants should
assess how well they performed on that topic and choose
one of the following descriptions: “very well”, “well”,
“satisfactory”, “deficient”, “inadequate”, “don’t know” and
“no answer”.
This open conversation is followed by a standardized
assessment of the following aspects:
– Changes in medication
– Side effects of the medication. The side-effects are
being assessed with the descriptions “no side effects”,
“little”, “moderately”, “strongly” and “very strong” for
each of the following: movement disorders, muscle
stiffness, involuntary shiver, motionlessness, muscle
Table 1 Interview questions and answers to assess acceptance and satisfaction of the participants
Question: How would you assess the telephone and text messages contacts during the last 6 months?
Answer: Very helpful – little helpful – not helpful – other (free text) – don’t know – no answer
Question: Could you imagine continuing the telephone contacts in this form?
Answer: Yes – No – don’t know – no answer
Question: Do you think this kind of care can partly replace personal contacts with physicians or psychologists?
Answer: Yes – No – don’t know – no answer
Question: Is there something you would change or improve?
Answer: Yes – No – don’t know – no answer and additional free text
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spasm, agonizing restlessness/problems to sit still
(can’t be suppressed at will), lack of sexual desire/
loss of libido, increase in weight, increased appetite,
heavy feeling of illness/chills/fever and milk flow.
– Medication intake. Assessment of adherence (e.g.
forgetting to take drugs, arbitrary changes in dose
or skipping doses).
– Suicidal tendencies. The assessment of suicidal
tendencies consists of asking for suicidal thoughts,
concrete intentions and plans: are these thoughts
imposing or conscious, talked to someone about,
reduction of interpersonal contacts and interests and
make contact to relatives or treating physician.
The intervention call ends with concluding remarks:
– What are you taking with you from the call today?
– Would you like to discuss another topic next time?
– Would you like to ask me something or do you have
another wish yet?
At the end, an appointment for the next call is made.
After each call, based on the information solicited, the
nurses rate the health conditions of the participant on the
basis of an adaption of the BPRS on a range from one
(minimal manifestation) to ten (maximal manifestation)
for each of the items: receptiveness/cooperation, concen-
tration, ability of vibration, Strain/nervousness, hostility,
distrust/paranoid thought content, uncooperative behav-
iour and unusual, bizarre thoughts of the patient.
The weekly text messages take up global themes such
as “I wish a good start in the week.” Or individual mes-
sages such as “You wanted to go to a choir practice. Did
you go and how was it?” The participants can answer
and the nurses will response if necessary or appropriate.
Documentation, data storage, data security and data
protection
The documentation of all data (baseline interview, docu-
mentation of the telephone calls and follow-up interviews)
is conducted on the basis of eCRFs in an IT-supported
documentation system [48]. The data is saved in a central
project database. The storage is done according to the
current standards for data security and data privacy [49].
These standards are documented in the institutional
data protection concept of the Institute for Community
Medicine and the telemedicine centre. Only the study
psychologist and the nurses have access to personal data
during the intervention phase. After completion the 6-
month-follow-up, the data will be pseudonymised and
identifying data will be separated from the project data
and kept in the independent trustee’s office of the
University Medicine Greifswald.
Ethics approval
The institutional ethics committee of the University
Medicine Greifswald evaluated the study, design and
instruments and testified the compliance with ethical
requirements at 2015\01\27 (registration number BB
122/14).
Trial registration
The Tecla study is registered at 2015\05\21 at the German
Clinical Trials Register (DRKS00008548).
Data analysis
Data analyses will be conducted in a strictly pseudony-
mised way. First, a descriptive analysis will be conducted.
All outcomes will be analysed as a comparison between
the groups at 3 and 6 months. Acceptance will be evalu-
ated only in the intervention group.
Discussion
A previous study for patients with anxiety, depressive
symptoms and somatization showed positive effects on
the symptom scores for anxiety and depression [50].
Based on these results, the outlined study was initiated
to improve the medical care for patients with severe
mental disorders. In most cases a lifelong medical treat-
ment is necessary, therefore, medication adherence is
very important, but low in many cases [14-16]. Regular
telephone calls and text messages might improve adher-
ent behaviour. Medication adherence is measured with
the self-report “Medication Adherence Report Scale”,
German version (MARS-D) [30]. Self-reports inhere the
risk of biased estimations. The original five item “Medi-
cation Adherence Report Scale” (MARS-5) was devel-
oped to minimize social desirability bias [34, 35]. Due to
the risk of selective drop out, a challenging part of this
study will be the performance of the follow-up examina-
tions after 3 and 6 months, in particular with patients of
the control group. Changing opinions, forgetting ap-
pointments for calls or rehospitalizations are probable
reasons for lost to follow-up, especially in this patient
group.
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